Half-Time for TBMED: 2021 Kicks Off with 4th Progress Meeting
TBMED started the new year and the second half of the project’s duration with its 4th Progress Meeting, held virtually from January 27-28, 2021. Despite working under the persistent constraints of the COVID-19 pandemic, which imposed some delays in the first half of 2020, the partners were able to adapt their workplan and make good progress on their objectives.
The TBMED scientific partners continue to work together closely on the three TBMED case studies focusing on glycobone, keratoprosthesis and hyperthermia treatment. While there are some minor issues reported during the meeting that need to be resolved over the next few months, the work in the case studies, and particularly the experience with overcoming problems, offers TBMED the unique opportunity to learn from them. The lessons learned will also be crucial for setting up the services for the future OITB.
Besides the scientific progress, building the OITB was the second focus of the TBMED meeting as it is projected to be launched by the end of the year. However, since the OITB will not be the only outcome of TBMED, the consortium held an exploitation workshop to identify the partners’ Key Exploitable Results stemming from their individual work in the project.
Overall, 2021 will be a very work-intensive but exciting project year to which all partners are looking forward.
TBMED is a four-year collaborative project funded under the European Union’s Horizon 2020 research and innovation programme. As one of the 13 European partners from Spain, France, Ireland and Germany, EURICE is involved in TBMED as a partner for project management and as the lead for activities related to communication, dissemination and exploitation.